3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
4
Completed
2
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell
18
Lymphoma, Mantle-Cell
13
Lymphoma, Non-Hodgkin
6
Lymphoma, Large B-Cell, Diffuse
6
Lymphoma
5
Lymphoma, B-Cell
4
Waldenstrom Macroglobulinemia
3
Lymphoma, Follicular
2
Lymphoma, B-Cell, Marginal Zone
2
Pyloric Stenosis, Hypertrophic
1
Part1: Advanced B-cell Malignancies
1
Neuritis
1
Neoplasms
1
Neoplasm, Residual
1
Lymphoproliferative Disorders
1
Lymphatic Diseases
1
Leukemia, Prolymphocytic
1
Leukemia, B-Cell
1
Leukemia
1
Hematologic Neoplasms
1
Hematologic Diseases
1
Glioblastoma
1
Cardiovascular Diseases
1
Anemia, Hemolytic, Autoimmune
1
Interventions
venetoclax
4
ibrutinib
4
obinutuzumab
3
fludarabine phosphate
3
fludarabine
3
Mesna
3
Cyclophosphamide
3
Whole-Body Irradiation
2
Tacrolimus
2
Peripheral Blood Stem Cell Transplantation
2
Patient Reported Outcome Measures
2
Mycophenolic Acid
2
Melphalan
2
Busulfan
2
zanubrutinib
1
ricolinostat
1
idelalisib
1
acalabrutinib
1
Bone Marrow Transplantation
1
Bendamustine Hydrochloride
1
ARQ531
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Leukemia, B-Cell
×
acalabrutinib
×
Clear all
NCT03836261
2024-12-27
AMPLIFY
Acerta Pharma BV
Phase 3
Active not recruiting
984 enrolled
1 FDA